| D010038 |
Otorhinolaryngologic Diseases |
Pathological processes of the ear, the nose, and the throat, also known as the ENT diseases. |
Otolaryngologic Diseases,ENT Diseases,Otolaryngological Diseases,Otorhinolaryngologic Disease,Otorhinolaryngological Disease,Disease, ENT,Disease, Otolaryngologic,Disease, Otolaryngological,Disease, Otorhinolaryngologic,Disease, Otorhinolaryngological,Diseases, ENT,Diseases, Otolaryngologic,Diseases, Otolaryngological,Diseases, Otorhinolaryngologic,Diseases, Otorhinolaryngological,ENT Disease,Otolaryngologic Disease,Otolaryngological Disease,Otorhinolaryngological Diseases |
|
| D002986 |
Clinical Trials as Topic |
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. |
Clinical Trial as Topic |
|
| D004341 |
Drug Evaluation |
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. |
Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation |
|
| D005938 |
Glucocorticoids |
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. |
Glucocorticoid,Glucocorticoid Effect,Glucorticoid Effects,Effect, Glucocorticoid,Effects, Glucorticoid |
|
| D006801 |
Humans |
Members of the species Homo sapiens. |
Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man |
|
| D006854 |
Hydrocortisone |
The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. |
Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol |
|
| D000463 |
Algestone Acetophenide |
A progesterone that has been used in ESTRUS SYNCHRONIZATION and has been evaluated as an injectable contraceptive in combination with estradiol enanthate. It is also applied topically as an anti-inflammatory and in the treatment of ACNE. |
Alphasone Acetophenide,Dihydroxyprogesterone Acetophenide,Pregn-4-ene-3,20-dione, 16,17-((1-phenylethylidene)bis(oxy))-, (16alpha(R))-,Acetophenide, Algestone,Acetophenide, Alphasone,Acetophenide, Dihydroxyprogesterone |
|
| D000523 |
Algestone |
A synthetic progestational dihydroxy derivative of PROGESTERONE. Its acetonide possesses anti-inflammatory properties. |
Alphasone,Dihydroxyprogesterone,Pregn-4-ene-3,20-dione, 16,17-dihydroxy-, (16alpha)-,16 alpha,17-Dihydroxypregn-4-ene-3,20-dione |
|